StockLearn from Clustermicro · Stock Breakout ScannerStockLearn
← All NSE stocks

Lyka Labs (LYKALABS)

Pharma · NSE · end-of-day 2026-11-17
Close
₹88.03
Day change
+1.99%
1-year
-6.4%
From 52-week high
-6.0%
Weinstein stage
Stage 2
Minervini template
8/8
Lyka Labs closed at ₹88.03 on 2026-11-17, up 2% over the past year, 6% below its 52-week high. It meets 8 of 8 conditions of Minervini's trend template - a full pass; Weinstein's stage analysis reads stage 2 - advancing; on earnings, it passes 3 of 4 SEPA checks. Over the year its annualised volatility was about 46%, with a largest fall of 52% from a peak.

Price, RSI and MACD

Price · +49.7% over the period
5664738190May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
RSI (14) · 69.0
305070
MACD (12, 26, 9) · histogram +1.10
-2.6-0.90.92.64.4
Price · -6.0% over the period
41587693110Nov 25Jan 26Mar 26May 26Jul 26Sep 26Nov 26
RSI (14) · 69.0
305070
MACD (12, 26, 9) · histogram +1.10
-5.5-3-0.52.14.6
Price · -39.3% over the period
3974110145181Feb 25Jun 25Oct 25Feb 26Jun 26Oct 26
RSI (14) · 69.0
305070
MACD (12, 26, 9) · histogram +1.10
-12.4-7.3-2.22.87.9
Price · -19.2% over the period
4477110143176Mar 24Aug 24Jan 25Jun 25Nov 25Apr 26Sep 26
RSI (14) · 69.0
305070
MACD (12, 26, 9) · histogram +1.10
-12.6-6.6-0.65.511.5
Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market capSales (TTM)Net profit (TTM)P/EEPS (TTM)P/BROEROCEDebt / equityFree cash flowBeta
₹318 cr₹138 cr₹-9 cr—-2.503.44-10.2%-6.0%0.52₹-6 cr1.14

Quarterly results

QuarterSales ₹ crNet profit ₹ crEPSEPS YoYSales YoYNet margin
Jun 20264220.57+128.0%+28.1%4.8%
Mar 202628-8-2.13-534.7%-16.2%-28.8%
Dec 202531-00.00-100.0%-9.1%-0.5%
Sep 202537-3-0.94-262.1%-10.9%-8.8%
Jun 20253310.25——3.0%
Mar 20253320.49——6.1%
Dec 20243430.75——8.0%
Sep 20244120.58——5.1%
Consolidated · EPS restated onto today's share count after splits and bonuses · net profit as filed.

Minervini SEPA — earnings checks 3 of 4 pass

CheckResult
Latest quarter EPS up 25%+ on a year ago✓ Pass
EPS growth positive and accelerating over 3 consecutive quarters✗ Fail
Sales up 25%+, or sales growth positive and accelerating✓ Pass
Annual EPS up 25%+ in each of the last 2 years (3 full years needed)— Not assessable
Net margin above the same quarter last year✓ Pass

Investor methods

MethodChecksScoreVerdict
Minervini
✓ Close above the 150- and 200-day averages
✓ 150-day above 200-day
✓ 200-day rising for a month
✓ 50-day above the 150- and 200-day
✓ Close above the 50-day
✓ At least 25% above the 52-week low · low 44.95
✓ Within 25% of the 52-week high · high 93.64
✓ RS percentile 70 or more · RS 79
Minervini's trend template - the gate the scanner applies.
8/8Pass
Weinstein
Stan Weinstein's stage analysis on the 30-week moving average.
Stage 2 - advancing
CAN SLIM
✓ C latest quarter EPS up 25%+, with sales up 25%+ or accelerating
— A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held
✓ N (proxy) near the 52-week high - within 15% · high 93.64
✓ S (proxy) more volume on up days than down days (50 sessions) · 2.30x
✗ L RS percentile 80 or more · RS 79
— I (proxy) FII + DII holding trend · not yet collected for this stock
✓ M (proxy) market in an uptrend, 40%+ of stocks above their 200-day - shared, not counted · breadth 51%
William O'Neil's growth-leader checklist, as a checklist score: the six stock letters counted equally, though O'Neil read them together. M is the market condition, shown but not counted. N, S, I and M are proxies.
3/4Average
Darvas
✗ New 52-week high in the last 120 sessions
Darvas needs a new 52-week high to start a box.
10/100No box
Turtle
✓ Close above the prior 55-session high · 88.00
✓ Close above the prior 20-session high · 87.79
✗ Close below the prior 20-session low (also a Turtle exit level) · 74.06
Turtle-inspired long breakout: the Turtle traders' entry channels only - no exits, stops or position sizing.
Breakout (55-day)
Graham
Needs positive earnings and book value.
Not assessable
Piotroski
✗ Profitable (ROA > 0, on beginning-of-year assets)
✓ Operating cash flow positive
— ROA rising · needs three years
✓ Cash flow above net profit (earnings quality)
— Long-term debt / average assets lower · needs three years
✗ Current ratio higher · 1.17
✓ No new equity issued
— Gross margin higher · not assessed - gross profit not filed here
— Asset turnover higher (sales / beginning assets) · needs three years
Piotroski F-score (adapted), FY 2025 -> 2026: 3 of 9 passed, 4 not assessed. Piotroski applied it to value stocks; here it is shown for all non-financial companies.
3/9Weak
Each method's own rules, applied to this stock - shown as information, not a buy or sell signal. All were tested on available data.

Pharma sector — top 10 by 1-year return

Stock1M %3M %6M %1Y %3Y %5Y %P/EP/BROE %ROCE %ROA %D/EEV/EBITDA₹ CrSales TTM ₹ CrProfit TTM ₹ CrEPSBeta
LYKALABS this stock+0.3+29.4+42.9+2.4-22.0-26.9—3.44-10.2-6.0-5.950.52—318138-9-2.51.14
BLISSGVS+0.7+26.1+136.4+301.9+405.5+549.543.15.4111.516.89.650.0024.86,9791,07416615.20.90
INDSWFTLAB-7.6+6.0+147.9+233.3+252.7+338.434.01.963.23.92.660.0119.82,886753849.80.60
VENUSREM-7.6-15.4+67.3+174.9+341.6—16.82.8916.821.913.100.0011.02,03983712291.00.87
BAFNAPH+2.5+83.5+249.6+161.1+492.4+229.597.310.8412.311.96.760.3653.21,119155124.90.37
SHILPAMED-2.2+13.3+91.7+144.7+388.1+224.553.76.519.811.46.940.2433.817,9421,84233217.10.74
ACUTAAS+23.0+23.3+44.4+130.7+624.3+690.773.517.3824.031.720.170.0049.632,2811,59243953.60.68
LAURUSLABS+13.5+29.2+76.6+128.8+532.1+383.194.220.8418.217.98.970.4166.81.26L7,8221,33224.80.66
RUBICON+11.6-6.4+75.2+126.9——85.419.6822.6——0.2854.227,8742,10032519.70.34
IOLCP-2.0+18.3+80.0+99.4+124.8+99.127.62.917.910.75.540.1015.75,5992,7512036.91.04
SAILIFE+26.1+23.7+60.6+99.1——98.513.8415.120.910.280.1753.537,2052,37237617.80.82
Returns are total over each period, not annualised - 5Y is the whole five-year change. A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Pharma stocks of a similar size

Aarey Drugs & PharmaceuticalsMedicamen BiotechNectar LifesciencesHaleos LabsWanburyMedico RemediesKronox Lab SciencesZim Laboratories

← All NSE stocks  ·  More Pharma stocks

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →
Prices as of 2026-11-17, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.
For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.